AR017796A1 - DERIVADOS DE 2-ARIL-8-OXODIHIDROPURINA, PROCEDIMIENTOS PARA PREPARARLOS, COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHOS PROCEDIMIENTOS, COMPOSICIONES FARMACEUTICAS, Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD. - Google Patents
DERIVADOS DE 2-ARIL-8-OXODIHIDROPURINA, PROCEDIMIENTOS PARA PREPARARLOS, COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHOS PROCEDIMIENTOS, COMPOSICIONES FARMACEUTICAS, Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD.Info
- Publication number
- AR017796A1 AR017796A1 ARP980106147A ARP980106147A AR017796A1 AR 017796 A1 AR017796 A1 AR 017796A1 AR P980106147 A ARP980106147 A AR P980106147A AR P980106147 A ARP980106147 A AR P980106147A AR 017796 A1 AR017796 A1 AR 017796A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- lower alkyl
- substituted
- alkyl group
- cycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 14
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Se revelan derivados de 2-aril-8-oxodihidropurina de la siguiente formula (I): donde W es un átomo de hidrogeno, un grupo alquilo inferior, un átomo dehalogeno, un grupo alcoxi inferior, un grupo amino, un grupo mono-o di-alquilo inferior-amino, oun grupo fenilo sustituido o no sustituido; X es un átomo dehidrogeno, un grupo alquilo inferior, un grupo cicloalquil-alquilo inferior, un grupo fenil-alquilo inferior sustituido o no sustituido, un grupo alqueniloinferior, un grupo carbamoílo, ungru po-dialquilo inferior carbamoílo, o un grupo de formula (Q): -CH(R3)CON(R1)(R2) (donde R1 es un grupo alquilo inferior, ungrupo alquenilo inferior, un grupo cicloalquilo, un grupo cicloalquil-alquilo inferior o un grupo hidroxi-alquilo, R2 es ungrup o alquilo inferior, un grupocicloalquilo, un grupo fenilo sustituido o no sustituido, un grupo fenil-alquilo inferior sustituido o no sustituido o un grupo heteroarilo sustituido o nosustituido, o R1 y R2 se pueden combinar juntos con el átomode nit rogeno adyacente para formar un anillo piperidínico, un anillo pirrolidínico, un anillomorfolínico o un anillo piperazíncio, y estos anillos opcionalmente pueden estar sustituidos por uno o dos grupos alquilo inferior, y R3 es un átomo de H,ungrupo alquilo inferior o un grupo hidroxi-alquilo inferior); Y es un átomo de H, un grupo alquilo inferior, un grupo cicloalquilo, un grupo cicloalquil-alquiloinferior, un grupo alquenilo inferior, un grupo fenil-alquilo inferior sustituido o nosustituido , o un grupo de formula (Q): -CH(R3)CON(R1)(R2), donde R1, R2y R3 son como fueron definidos anterioremente; y A es un grupo fenilo sustituido o no sustituido o un grupo heteroarilo sustituido o no sustituido;si se da quede X e Y de laformula anterio r (I) es el grupo de formula (Q), entonces el otro es uno de los mismos grupos que están para X o Y, como fue descritoanteriormente, excepto el grupo de formula (Q), o una sal por adicion de ácido farmacéuticamente aceptable delmismo. También se pro ponen la preparacionde dichos compuestos y los objetos secundarios mencionados. Dichos derivados son de aplicacion farmacéutica por su actividad selectiva sobre los
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35000097 | 1997-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR017796A1 true AR017796A1 (es) | 2001-10-24 |
Family
ID=18407561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106147A AR017796A1 (es) | 1997-12-03 | 1998-12-03 | DERIVADOS DE 2-ARIL-8-OXODIHIDROPURINA, PROCEDIMIENTOS PARA PREPARARLOS, COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHOS PROCEDIMIENTOS, COMPOSICIONES FARMACEUTICAS, Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6372740B1 (es) |
| EP (1) | EP1036794B1 (es) |
| JP (1) | JP3815966B2 (es) |
| KR (1) | KR100494347B1 (es) |
| CN (1) | CN1146566C (es) |
| AR (1) | AR017796A1 (es) |
| AT (1) | ATE248169T1 (es) |
| AU (1) | AU744014B2 (es) |
| BR (1) | BR9815140A (es) |
| CA (1) | CA2312885C (es) |
| DE (1) | DE69817611T2 (es) |
| DK (1) | DK1036794T3 (es) |
| ES (1) | ES2205574T3 (es) |
| HK (1) | HK1028769A1 (es) |
| HU (1) | HUP0004422A3 (es) |
| ID (1) | ID24929A (es) |
| IL (1) | IL135920A0 (es) |
| NO (1) | NO20002835L (es) |
| NZ (1) | NZ504457A (es) |
| PL (1) | PL191489B1 (es) |
| PT (1) | PT1036794E (es) |
| RU (1) | RU2223272C2 (es) |
| SK (1) | SK285703B6 (es) |
| TR (1) | TR200001600T2 (es) |
| TW (1) | TW502034B (es) |
| WO (1) | WO1999028320A1 (es) |
| ZA (1) | ZA9810490B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003146987A (ja) * | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | ２−アリールプリン−９−アセトアミド誘導体 |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| CN1399632A (zh) * | 1999-09-27 | 2003-02-26 | 小野药品工业株式会社 | 嘧啶衍生物、其制备方法和含有该化合物作为有效成分的药物 |
| WO2002010167A1 (fr) * | 2000-07-31 | 2002-02-07 | Dainippon Pharmaceutical Co., Ltd. | Medicaments contre la demence contenant des derives de 2-aryl-8-oxodihydropurine comme ingredient actif |
| CA2554566A1 (en) * | 2003-08-05 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
| CA2554774A1 (en) * | 2004-02-23 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | Novel heterocyclic compound |
| WO2005115399A2 (en) * | 2004-04-16 | 2005-12-08 | Neurogen Corporation | Imidazopyrazines, imidazopyridines, ans imidazopyrimidines as crf1 receptor ligands |
| FR2870239B1 (fr) | 2004-05-11 | 2006-06-16 | Sanofi Synthelabo | Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique. |
| US7884109B2 (en) * | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| NZ562468A (en) * | 2005-04-05 | 2009-10-30 | Pharmacopeia Inc | Purine and imidazopyridine derivatives for immunosuppression |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| US20070225304A1 (en) * | 2005-09-06 | 2007-09-27 | Pharmacopeia Drug Discovery, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| US7989459B2 (en) * | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| US20090281075A1 (en) * | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| US7951803B2 (en) * | 2006-03-09 | 2011-05-31 | Pharmacopeia, Llc | 8-heteroarylpurine MNK2 inhibitors for treating metabolic disorders |
| AR063142A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
| US7902187B2 (en) * | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| WO2008043019A1 (en) * | 2006-10-04 | 2008-04-10 | Pharmacopeia, Inc | 8-substituted 2-(benzimidazolyl) purine derivatives for immunosuppression |
| RU2478635C2 (ru) | 2006-10-19 | 2013-04-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, содержащие их композиции и способы лечения с применением этих соединений |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| JP2009007273A (ja) * | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US8473571B2 (en) | 2009-01-08 | 2013-06-25 | Microsoft Corporation | Synchronizing presentation states between multiple applications |
| CN102656172B (zh) * | 2009-09-09 | 2016-03-23 | 大日本住友制药株式会社 | 8-氧代二氢嘌呤衍生物 |
| EP2493472B1 (en) | 2009-10-26 | 2016-12-07 | Signal Pharmaceuticals, LLC | Methods of synthesis and purification of heteroaryl compounds |
| JP2014076947A (ja) * | 2011-02-03 | 2014-05-01 | Dainippon Sumitomo Pharma Co Ltd | ２−オキシ置換８−オキソジヒドロプリン誘導体 |
| WO2012168697A1 (en) | 2011-06-06 | 2012-12-13 | Imperial Innovations Limited | Methods to predict binding affinity of tspo imaging agents to tspo |
| CN107157990B (zh) | 2011-10-19 | 2020-01-07 | 西格诺药品有限公司 | 利用tor激酶抑制剂治疗癌症 |
| UA114496C2 (uk) | 2011-12-02 | 2017-06-26 | Сігнал Фармасьютікалз, Елелсі | ФАРМАЦЕВТИЧНІ КОМПОЗИЦІЇ 7-(6-(2-ГІДРОКСИПРОПАН-2-ІЛ)ПІРИДИН-3-ІЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГІДРОПІРАЗИНО[2,3-b]ПІРАЗИН-2(1H)-ОНУ, ЇХ ТВЕРДІ ФОРМИ І СПОСОБИ ЇХ ЗАСТОСУВАННЯ |
| EA028462B1 (ru) | 2012-02-24 | 2017-11-30 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Способы лечения немелкоклеточного рака легких на поздних стадиях c применением комбинированного лечения с ингибитором киназы tor |
| CN102675315B (zh) * | 2012-02-28 | 2015-04-01 | 中国人民解放军第四军医大学 | 含取代苯烷基的嘌呤类化合物和制备方法及应用 |
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| BR112015016997A2 (pt) | 2013-01-16 | 2017-07-11 | Signal Pharm Llc | composto, composição farmacêutica e método para o tratamento ou prevenção de câncer de mama |
| US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| CA2908353C (en) | 2013-04-17 | 2021-11-02 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| JP6382948B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのｔｏｒキナーゼ阻害剤及びシチジン類似体を含む組合せ療法 |
| TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於１－乙基－７－（２－甲基－６－（１Ｈ－１，２，４－三唑－３－基）吡啶－３－基）－３，４－二氫吡并［２，３－ｂ］吡－２（１Ｈ）－酮之醫藥調配物、方法、固態型式及使用方法 |
| BR112015026297B1 (pt) | 2013-04-17 | 2022-08-23 | Signal Pharmaceuticals, Llc | Uso de um inibidor da quinase tor e quinazolinona 5-substituída, composição farmacêutica que os compreende, e kit |
| US9358232B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| WO2014172426A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CN113831345A (zh) | 2013-05-29 | 2021-12-24 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| EP3131551A4 (en) | 2014-04-16 | 2017-09-20 | Signal Pharmaceuticals, LLC | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| WO2015160882A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| JP2017514806A (ja) | 2014-04-16 | 2017-06-08 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 |
| AU2015289929A1 (en) | 2014-07-14 | 2017-03-02 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| SG11201804098TA (en) | 2015-11-20 | 2018-06-28 | Forma Therapeutics Inc | Purinones as ubiquitin-specific protease 1 inhibitors |
| JP7282045B2 (ja) | 2017-06-22 | 2023-05-26 | セルジーン コーポレイション | Ｂ型肝炎ウイルス感染を特徴とする肝細胞癌の治療 |
| EP3752505B1 (en) | 2018-02-12 | 2023-01-11 | F. Hoffmann-La Roche AG | Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2525595A1 (fr) | 1982-04-27 | 1983-10-28 | Pharmuka Lab | Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments |
| FR2582514B1 (fr) | 1985-05-30 | 1988-02-19 | Rhone Poulenc Sante | Medicaments a base d'amides, nouveaux amides et leur preparation |
| DK273689A (da) | 1988-06-06 | 1989-12-07 | Sanofi Sa | 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler |
| FR2632639B1 (fr) | 1988-06-09 | 1990-10-05 | Sanofi Sa | Derives d'amino-4 carboxy-3 naphtyridines, leur preparation et compositions pharmaceutiques qui les contiennent |
| US6083953A (en) | 1994-07-28 | 2000-07-04 | Syntex (U.S.A.) Inc. | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
| IL117659A (en) | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| US6028076A (en) | 1996-07-03 | 2000-02-22 | Japan Energy Corporation | Purine derivative |
| NZ335823A (en) * | 1997-04-22 | 2001-06-29 | Neurocrine Biosciences Inc | Thiophenopyridines, preparation as CRF receptor antagonists |
| JP3814125B2 (ja) * | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬 |
-
1998
- 1998-11-17 ZA ZA9810490A patent/ZA9810490B/xx unknown
- 1998-11-25 TW TW087119571A patent/TW502034B/zh not_active IP Right Cessation
- 1998-11-26 DK DK98955937T patent/DK1036794T3/da active
- 1998-11-26 KR KR10-2000-7005968A patent/KR100494347B1/ko not_active IP Right Cessation
- 1998-11-26 JP JP2000523212A patent/JP3815966B2/ja not_active Expired - Fee Related
- 1998-11-26 TR TR2000/01600T patent/TR200001600T2/xx unknown
- 1998-11-26 BR BR9815140-1A patent/BR9815140A/pt not_active Application Discontinuation
- 1998-11-26 NZ NZ504457A patent/NZ504457A/en unknown
- 1998-11-26 AT AT98955937T patent/ATE248169T1/de not_active IP Right Cessation
- 1998-11-26 HU HU0004422A patent/HUP0004422A3/hu unknown
- 1998-11-26 RU RU2000117278/04A patent/RU2223272C2/ru not_active IP Right Cessation
- 1998-11-26 PL PL340925A patent/PL191489B1/pl unknown
- 1998-11-26 WO PCT/JP1998/005320 patent/WO1999028320A1/ja active IP Right Grant
- 1998-11-26 ES ES98955937T patent/ES2205574T3/es not_active Expired - Lifetime
- 1998-11-26 CA CA002312885A patent/CA2312885C/en not_active Expired - Fee Related
- 1998-11-26 PT PT98955937T patent/PT1036794E/pt unknown
- 1998-11-26 AU AU12604/99A patent/AU744014B2/en not_active Ceased
- 1998-11-26 SK SK797-2000A patent/SK285703B6/sk unknown
- 1998-11-26 DE DE69817611T patent/DE69817611T2/de not_active Expired - Fee Related
- 1998-11-26 EP EP98955937A patent/EP1036794B1/en not_active Expired - Lifetime
- 1998-11-26 ID IDW20000990A patent/ID24929A/id unknown
- 1998-11-26 IL IL13592098A patent/IL135920A0/xx not_active IP Right Cessation
- 1998-11-26 CN CNB988134519A patent/CN1146566C/zh not_active Expired - Fee Related
- 1998-11-26 US US09/555,490 patent/US6372740B1/en not_active Expired - Fee Related
- 1998-12-03 AR ARP980106147A patent/AR017796A1/es active IP Right Grant
-
2000
- 2000-06-02 NO NO20002835A patent/NO20002835L/no unknown
- 2000-12-15 HK HK00108107A patent/HK1028769A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR017796A1 (es) | DERIVADOS DE 2-ARIL-8-OXODIHIDROPURINA, PROCEDIMIENTOS PARA PREPARARLOS, COMPUESTOS INTERMEDIARIOS DE APLICACIoN EN DICHOS PROCEDIMIENTOS, COMPOSICIONES FARMACEUTICAS, Y SU USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ESTADOS DE ANSIEDAD. | |
| MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
| UY26258A1 (es) | Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona. | |
| NO963053D0 (no) | Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| AR006678A1 (es) | Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion | |
| BR0015605A (pt) | Composição e uso | |
| AR018732A1 (es) | Iminoazucares alquilados para prevenir, reducir o revertir la resistencia a la multidroga en el tratamiento quimioterapeutico y composicionfarmaceutica que los contiene. | |
| ECSP034660A (es) | Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen | |
| AR015987A1 (es) | DERIVADOS DE PLEUROMUTILINA, COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE, Y, SU USO PARA LA ELABORACIoN DE UN MEDICAMENTO. | |
| AR029210A1 (es) | DERIVADOS DE N-(5-SULFAMOIL-1,3-TIAZOL-2-IL) ACETAMIDA, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTOS INTERMEDIARIOS, COMPOSICIoN FARMACÉUTICA, Y EL USO DE DICHOS DERIVADOS PARA LA PRODUCCIoN DE MEDICAMENTOS | |
| ES2061848T3 (es) | Compuestos triciclos, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden. | |
| PA8451801A1 (es) | Derivados de la 9-oxima eritromicina | |
| AR029151A1 (es) | Una sal cuaternaria de piperidina, su uso, un proceso para su preparacion, y una composicion farmaceutica que la contiene | |
| ES2061462T3 (es) | Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| EA199800938A1 (ru) | Композиции, содержащие антигрибковый агент и ацетатный буфер | |
| PA8485601A1 (es) | Azalidas de 13 miembros y su uso como agentes antibioticos. | |
| AR015434A1 (es) | Derivados de eritromicina con puente en 6,9, procedimientos para su preparacion, composicion farmaceutica para tratar infecciones bacterianas que los contiene y su uso para la manufactura de un medicamento | |
| ES2105286T3 (es) | Derivados de etanolamina que tienen actividades simpatomimetica y anti-polaquiuria. | |
| AR014554A1 (es) | Compuestos polipeptidos, utiles para el tratamiento de infecciones microbianas, procedimiento para prepararlos, composiciones y medicamentos quelos incluyen y el uso de dichos compuestos y metodo para el tratamiento profilactico y terapeutico de infecciones | |
| TR200000153T2 (tr) | İl-5 inhibite eden 6-azaurasil türevleri. | |
| CO5070654A1 (es) | Derivados de acidos fenilaminoalquilcarboxilicos y composiciones farmaceuticas que los comprenden | |
| DK0527081T3 (da) | Hidtil ukendte substituerede 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-oner, deres fremstilling og terapeutiske anvendelse | |
| AR004691A1 (es) | Nuevos derivados de [3-alcoxi-fenoxi-)-etil]-dialquilamina, una composicion farmaceutica que los comprende, su uso como anestesicos locales y unprocedimiento para su preparacion | |
| BRPI9509819B8 (pt) | benzamida enterocinética e composição farmacêutica compreendendo a mesma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |